Key clinical point: Subcutaneous hepatitis A vaccination is as immunogenic, but appeared safer than intramuscular injections for bleeding disorder patients.
Major finding: A total of 38 patients assessed after first vaccine dose showed seroconversion rates of 83.3% and 90.0% for the subcutaneous versus the intramuscular group, respectively.
Study details: A comparison of hepatitis A vaccination administered subcutaneously or intramuscularly in 78 children and adults with hemophilia and other bleeding disorders.
Disclosures: The authors declared that they had no disclosures.
Nakasone M et al. Vaccine. 2020;38:4162-6.